Last updated: February 16, 2026
Product Overview:
NDC 00517-4810 is branded as Veklury (remdesivir) by Gilead Sciences. It is an antiviral medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of COVID-19 in hospitalized patients, as well as other viral infections. The drug gained prominence during the pandemic, with sales largely driven by COVID-19 treatment needs.
Market Landscape
1. Market Scope & Demand Dynamics
Remdesivir’s demand originated in response to COVID-19, initially driven by emergency use authorizations (EUAs) and later full approval. The market was substantial during the pandemic but has experienced a decline post-pandemic due to the emergence of oral antivirals and changing treatment guidelines.
- Demand Trends:
- Peak sales in 2021 exceeded $2.5 billion globally.
- Sales declined 60% in 2022 following the FDA’s 2022 recall of EUAs for COVID-19 indications in certain contexts and the advent of alternatives.
- Current demand is primarily driven by specific hospital use cases for severe COVID-19 and emerging indications for other viral infections.
2. Competitive Environment
Key competitors include oral antivirals like Pfizer's Paxlovid (nirmatrelvir/ritonavir) and Merck's Lagevrio (molnupiravir). These drugs offer easier administration routes, reducing reliance on intravenous delivery typical of remdesivir.
- Market Share:
- In 2022, remdesivir held approximately 40% of hospital-based COVID-19 antiviral sales in the U.S., down from 85% during the initial pandemic phase ([1]).
3. Regulatory Status & Approvals
- FDA full approval (August 2020) for hospitalized COVID-19 patients.
- The CDC and NIH recommend remdesivir primarily for hospitalized or severe cases.
- Ongoing research explores other indications, including hepatitis C co-infection and emerging viral diseases.
4. Price and Pricing Trends
- Gilead's list price for a 100 mg vial is approximately $330.
- Treatment course for hospitalized patients typically involves six Vials ($1,980 total per patient).
- Actual prices paid by hospitals or payers are generally discounted via negotiated pricing and bulk purchasing agreements.
Price Projections
1. Short-term Outlook (Next 1-2 Years)
- Continued decline in sales expected due to competition from oral agents and evolving treatment protocols.
- Gilead might sustain sales via expanding indications and geographic markets.
- Price per vial likely remains stable or decreases marginally, reflecting increased competition and generic entry in some markets.
2. Mid-term Outlook (3-5 Years)
- Reduced sales volumes as COVID-19 transitions to endemic status.
- Potential for price erosion if biosimilar or generic versions enter markets in Europe or other regions.
- Gilead may explore licensing or partnership strategies to maintain revenue streams.
3. Long-term Outlook (Beyond 5 Years)
- Likelihood of negligible sales unless new indications emerge.
- Price probably stabilizes at levels close to current, adjusted for inflation and market conditions.
4. Impact of Policy & Market Factors
- Pricing sensitivity influenced by government procurement and reimbursement policies.
- USA government’s stockpiling policies have historically inflated initial prices but are less active now.
- Global health initiatives could expand access at lower prices in developing markets.
Key Data Summary
| Parameter |
Value/Trend |
Notes |
| 2022 global sales |
<$1 billion |
Declined from peak in 2021 |
| Price per vial |
~$330 |
Listed to hospitals |
| Expected sales (2023–2024) |
Further decline |
Due to competition and reduced COVID-19 cases |
| Market share |
40% (2022 in U.S.) |
Down from 85% (2021) |
| Launch indications |
Current for severe COVID-19; expanding |
Research ongoing for other viral infections |
Key Takeaways
- The COVID-19 pandemic initially drove rapid growth in remdesivir sales, with peak global revenue exceeding $2.5 billion in 2021.
- Sales have declined sharply as newer oral antivirals gained approval and treatment protocols shifted.
- The price per vial remains around $330, but actual transaction prices are lower due to negotiations.
- The future market is limited mainly to hospital settings and severe cases, with expected continued decline.
- Price stabilization or erosion will depend on regulatory developments, new indications, competition, and regional policy changes.
FAQs
1. Will remdesivir regain market share?
Unlikely. The shift to oral therapies and reduced severity COVID-19 cases diminish the need for intravenous remdesivir.
2. Are there patent expirations or biosimilar entries planned?
No clear biosimilar entrants are announced yet, but expiration of patents in certain regions may accelerate price erosion in the longer term.
3. Could regulatory changes expand remdesivir’s indications?
Potentially. Ongoing research into other viral infections could open alternative markets, influencing demand.
4. How does Gilead's pricing compare internationally?
Pricing varies by country, often lower in Europe and developing countries due to negotiated healthcare agreements and generic availability.
5. What is the outlook for Gilead's revenue from remdesivir?
It remains a revenue contributor but is expected to decrease sharply over the next few years unless new indications or markets materialize.
Sources
[1] IQVIA, 2022; Gilead Sciences annual report, 2022; CDC guidelines; FDA approvals and labels.
